Our company, BioPhenoMA Inc., is a life science startup established in April 2023.

We were founded with the aim of revolutionizing protein quantitative measurement in the world of clinical testing and analysis, based on TN-cyclon™, a highly sensitive ultra-trace protein detection technology invented by Professor Etsuro Ito of Waseda University. Based on our core technology that enables highly sensitive quantitative measurement, we will develop applications and services in fields such as drug discovery and biomarker seed discovery.

Additionally, we will prioritize products in areas of high societal need, such as cancer and neurodegenerative diseases, and promote the development and launch of groundbreaking in vitro diagnostics (IVDs) and companion diagnostics (CDx) that serve as indicators for determining therapeutic drug selection.

Furthermore, in the field of infectious diseases, we hope to contribute to the field of global health with our technology, aiming to eradicate diseases that are spreading worldwide and posing a threat to tropical regions in particular.

BioPhenoMA will continue to contribute to the promotion of people's health through the research, development, and sale of these high-value-added testing and diagnostic products.

Our business theme is to quantify and clarify the "pre-illness" state, which is the boundary between health and illness, and link it to treatment, thereby promoting early detection, early treatment, and preventive medicine. With the theme of "quantifying pre-illness and linking it to treatment," we will continue to work to realize a healthy and prosperous society through testing.

As part of my various social activities over the past 35 years, I have worked hard to support cancer patients and their families, including building medical systems and infrastructure, reforming the social system, establishing the Japan Bone Marrow Donor Bank, and building international networks.

We will continue to create a society that contributes to people's health through medical care.